pSivida eyes Iluvian
Friday, 13 March, 2009
pSivida has reported good interim results in its Phase II study of the intra-vitreal insert Iluvien.
The 36-month open label study is being conducted by pSivida’s licensing partner Alimera Sciences and is being run concurrently with a Phase III trial of a corticosteroid in patients with diabetic macular oedema.
Data from the first 12 months showed no adverse events in lose dose patients while there was a small increase in intra-ocular pressure in high dose patients.
Iluvian delivers the drug fluocinolone acetonide directly into the eye. pSivida has licensed two other ophthalmic products, Retisert and Vitrasert, to Bausch & Lomb.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
